Johnson & Johnson (NYSE:JNJ) Stake Raised by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. boosted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,379,611 shares of the company’s stock after buying an additional 160,427 shares during the quarter. Johnson & Johnson makes up about 4.4% of Mawer Investment Management Ltd.’s holdings, making the stock its 5th biggest position. Mawer Investment Management Ltd. owned about 0.17% of Johnson & Johnson worth $773,658,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Nordwand Advisors LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at approximately $785,273,000. Savant Capital LLC lifted its stake in shares of Johnson & Johnson by 8,568.8% during the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after purchasing an additional 3,588,251 shares during the period. Edmp Inc. lifted its stake in shares of Johnson & Johnson by 17,222.9% during the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after purchasing an additional 3,204,658 shares during the period. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. Finally, GQG Partners LLC lifted its stake in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $160.78 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a 50-day moving average of $159.10 and a two-hundred day moving average of $166.73. The stock has a market cap of $417.82 billion, a P/E ratio of 33.64, a PEG ratio of 2.77 and a beta of 0.53. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.67 EPS. On average, research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 99.58%.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Guggenheim assumed coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 1st. StockNews.com assumed coverage on Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Credit Suisse Group upped their price objective on Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Finally, UBS Group assumed coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.